Does CYP3A5 polymorphism influence everolimus intestinal and hepatic metabolism?

被引：0
|
作者：
Rouguieg-Malki, K.
Picard, N.
Marquet, P.
机构：
[1] Univ Limoges, UMR S 850, INSERM, Limoges, France
[2] CHU Limoges, Limoges, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
346
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [21] CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics
    Venkatakrishnan, Karthik
    Gibbs, Megan A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 719 - 720
  • [22] Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism
    Mishima, Mizuki
    Yabe, Tomohisa
    Kondo, Takaya
    Fujimoto, Keiji
    Takata, Ryoji
    Yokoyama, Hitoshi
    Niida, Yo
    Tanaka, Tatsuro
    Miyazawa, Katsuhito
    Furuichi, Kengo
    CLINICAL CASE REPORTS, 2024, 12 (09):
  • [23] Contribution of CYP3A5 to the hepatic clearance of tarolimus
    Kamdem, LK
    Streit, F
    Zanger, MU
    Brockmöller, J
    Oellerich, M
    Armstrong, VW
    Wojnowski, L
    DRUG METABOLISM REVIEWS, 2005, 37 : 50 - 51
  • [24] Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients
    Nie, XM
    Gui, R
    Zhao, HS
    Ma, DL
    Li, DQ
    Yuan, H
    Huang, ZF
    JOURNAL OF CENTRAL SOUTH UNIVERSITY OF TECHNOLOGY, 2005, 12 (Suppl 1): : 310 - 312
  • [25] Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients
    Xin-min Nie
    Rong Gui
    Hong-shan Zhao
    Da-long Ma
    Deng-qing Li
    Hong Yuan
    Zu-fa Huang
    Journal of Central South University of Technology, 2005, 12 : 310 - 312
  • [26] Comparative drug metabolism by CYP3A4 and CYP3A5
    Huang, WL
    Lin, YS
    Dai, Y
    Totah, RA
    Calamia, JC
    Thummel, KE
    DRUG METABOLISM REVIEWS, 2003, 35 : 187 - 187
  • [27] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [28] Selective metabolism of vincristine in vitro by CYP3A5
    Dennison, Jennifer B.
    Kulanthaivel, Palaniappan
    Barbuch, Robert J.
    Renbarger, Jamie L.
    Ehlhardt, William J.
    Hall, Stephen D.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (08) : 1317 - 1327
  • [29] Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem
    Yamamoto, T
    Kubota, T
    Ozeki, T
    Sawada, M
    Yokota, S
    Yamada, Y
    Kumagai, Y
    Iga, T
    CLINICA CHIMICA ACTA, 2005, 362 (1-2) : 147 - 154
  • [30] CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics -: Reply
    Park, Ji-Young
    Kim, Kyoung-Ah
    Shin, Jae-Gook
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) : 720 - 720
12345